Clinical Trials

NCT Number: NCT05765500 Phase: Trial Summary: This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. T – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Dana-Farber Cancer Institute Acronym:

NCT Number: NCT05849298 Phase: Trial Summary: The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in pa – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Novartis Pharmaceuticals Acronym: PSMACare

NCT Number: NCT05794906 Phase: Phase 3 Trial Summary: Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Bayer Acronym: ARASTEP

NCT Number: NCT04300855 Phase: Phase 2 Trial Summary: This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of wh – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Acronym:

NCT Number: NCT04420702 Phase: Not Applicable Trial Summary: Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically si – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Washington University School of Medicine Acronym:

NCT Number: NCT04815876 Phase: NA Trial Summary: Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistanc – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: PREVENT2

NCT Number: NCT04984343 Phase: Phase 2 Trial Summary: The study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with lo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: FORT

NCT Number: NCT05424783 Phase: Not Applicable Trial Summary: The overarching goal is to prospectively recruit men considering active surveillance for treatment in the MAGIC (MRI And GPS Informing Choices for prostate cancer treatment) Cohort – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Northwestern University Acronym: MAGIC

NCT Number: NCT05668351 Phase: NA Trial Summary: This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Medical University of South […]

NCT Number: NCT04396808 Phase: Not Applicable Trial Summary: This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC cl – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Michigan Rogel Cancer Center Acronym: